arrow
P

Praful Ravi

Dana-Farber Cancer Institute
H指数:31
被引数:3,603

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer

基线和早期中性粒细胞-淋巴细胞比率作为177Lu-PSMA-617治疗晚期前列腺癌的预后生物标志物

2026-11-140
PRE
6 Antitumor Activity of 177Lu-PSMA-617 in PSMA-Positive Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Results from a Phase 2 Trial (LASER)

6 177Lu-PSMA-617在PSMA阳性转移性透明细胞肾细胞癌(ccRCC)中的抗肿瘤活性:来自一项2期试验(LASER)的结果

2026-09-020
OAAI
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析:激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

2025-11-040
PRE
Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging

骨髓疾病对血液学毒性和[177Lu]Lu-PSMA-617治疗反应的影响:来自PSMA-PET/CT成像的见解

2025-09-050
PRE
Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials

对转移性去势敏感前列腺癌患者生存结局的影响:一项随机III期临床试验的Meta分析

2025-05-010
PRE
Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer

联合转移灶靶向外照射放射治疗与177Lu-PSMA-617在晚期去势抵抗性前列腺癌患者中的应用

2025-04-220
PRE
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

177Lu-Vipivotide Tetraxetan治疗后转移性去势抵抗性前列腺癌的后续治疗方案结果:一家三级癌症中心的经验

2025-03-180
PRE
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

联合固定疗程系统性治疗和转移灶定向放疗治疗寡转移性激素敏感性前列腺癌

2024-11-010
PRE
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617

接受 [177Lu]Lu- PSMA-617治疗的转移性去势抵抗性前列腺癌和肝转移患者的预后

2024-10-300
PRE
Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform

使用一种新型表观基因组液体活检平台对血液中前列腺癌的肿瘤PSMA表达进行测定

2024-09-010
PRE
A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results

一项多队列II期临床试验,研究雄激素剥夺疗法(ADT)、多西他赛(DOCE)和纳武利尤单抗(NIVO)在富集了炎症肿瘤和DNA损伤修复(DDR)改变的新诊断转移性激素敏感性前列腺癌(mHSPC)患者(pts)中的应用:队列3结果

2024-09-010
PRE
Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)

更新后的双抗体药物偶联物(DAD)I期临床试验疗效概况:Sacituzumab govitecan(SG)联合Enfortumab vedotin(EV)在转移性尿路上皮癌(mUC)中≥二线治疗的疗效情况

2024-09-010
PRE
Insulin resistance during androgen deprivation therapy in men with prostate cancer

前列腺癌男性雄激素剥夺治疗期间的胰岛素抵抗

CANCER
IF5.1
2024-06-162
PRE